Yazılar

Siemens Healthineers Shares Rise on Q1 Revenue Beat Despite China Order Delays

/in /tarafından

Siemens Healthineers (SHLG.DE) reported stronger-than-expected first-quarter revenue on Thursday, with a 5.9% year-on-year increase, despite challenges posed by delayed customer orders in China. The company’s Q1 group revenue reached 5.48 billion euros ($5.69 billion), slightly surpassing the 5.37 billion euros forecast by analysts.

The revenue boost was driven by a 16% surge in U.S. revenues, counteracting a 6% decline in sales from China, which the company attributed to “continued delays in customer orders.” Like many of its peers in the healthcare technology sector, Siemens Healthineers has been impacted by China’s ongoing anti-corruption campaign, leading to reduced hospital equipment orders in the region.

Siemens Healthineers’ Chief Financial Officer, Jochen Schmitz, stated that the company expects continued challenges in China, forecasting a decline in sales in the “medium to high percentage range” during the first half of the year. He also noted a “flat trend” in China’s performance over the following quarters.

Despite the challenges, Siemens Healthineers remains cautiously optimistic, with CEO Bernd Montag emphasizing that while global trade disruptions, such as U.S. tariffs on imports from Mexico and Canada, are a concern, the risk to the healthcare and medical technology sectors remains relatively low. He added that U.S. tariffs on Chinese imports would have a “minor” impact on the company’s business.

The company also expects a stronger U.S. dollar to play a role in its financial outlook. Siemens Healthineers confirmed its full-year guidance, with revenue growth anticipated to fall within the lower end of the projected range of 5% to 6% for the second quarter.

 

Philips Sells Xiver Chipmaking Subsidiary, Report Reveals

/in /tarafından

Philips, the global healthcare technology company, has sold its small chipmaking subsidiary, Xiver, according to a report by the Telegraaf newspaper, citing the company’s CEO. The subsidiary was acquired by a consortium led by Orange Mills Ventures, the investment firm of Dutch businessman Cees Meeuwis. The financial details of the transaction were not disclosed.

Xiver, which specializes in manufacturing micro-electromechanical systems (MEMS)—a combination of mechanical and electronic components on a silicon chip—had been struggling financially and was described as a loss-making business. The subsidiary employed around 100 people. CEO John van Soerland, who retired from VDL last year, confirmed that Xiver supplies to major industry players, including ASML and the French defense firm Lynred.

Philips, which sold most of its semiconductor-related businesses, including ASML, several years ago, has since focused its efforts primarily on the healthcare sector. Xiver’s sale marks another step in the company’s strategy to streamline its operations, continuing its shift away from semiconductor manufacturing. Philips’ former semiconductor businesses, which include NXP and Nexperia, have now been spun off into separate entities.

 

Merck Signs $2 Billion Licensing Deal for Weight Loss Pill with Chinese Drugmaker Hansoh Pharma

/in /tarafından

Merck announced on Wednesday that it has secured the rights to an experimental weight loss pill from Chinese drugmaker Hansoh Pharma in a deal worth up to $2 billion. This oral drug, currently not in human trials, could position Merck to capitalize on the rapidly expanding obesity drug market, which analysts predict could exceed $100 billion annually by the early 2030s.

While Merck did not specify the diseases it plans to target first with this drug, the deal significantly boosts its potential in the obesity treatment field. The move comes as several other pharmaceutical companies, including Pfizer and Roche, are working to develop competitive oral weight loss medications that can challenge the blockbuster injectable drugs from Novo Nordisk and Eli Lilly.

Under the terms of the agreement, Merck will receive exclusive global rights to develop, manufacture, and commercialize Hansoh Pharma’s HS-10535, an oral drug targeting GLP-1, a gut hormone. GLP-1 is the same target for Novo Nordisk’s popular weight loss drug Wegovy and diabetes medication Ozempic, which work by suppressing appetite and regulating blood sugar levels.

Merck will pay Hansoh Pharma an upfront fee of $112 million for the licensing rights to the drug. Additionally, the deal includes up to $1.9 billion in milestone payments and royalties on future sales, according to a press release from the company.

Merck’s president of Research Laboratories, Dean Li, expressed confidence in the drug’s potential, noting it could offer “additional cardiometabolic benefits beyond weight reduction.” The company has been actively seeking GLP-1 treatments that provide not just weight loss but other health benefits, such as improvements in cardiovascular health, diabetes, and fatty liver disease. Merck CEO Rob Davis highlighted this strategic focus in early 2023, stating that therapies with broader health benefits would be crucial for obtaining reimbursement and establishing long-term market success.

This agreement with Hansoh Pharma adds to the growing trend of Chinese companies entering the global market for GLP-1-based treatments. In a similar deal last year, AstraZeneca licensed an experimental oral GLP-1 drug from Chinese company Eccogene, which is currently in mid-stage development.